IO Biotech announces publication of preclinical data on IO112

IO Biotech (IOBT) announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, in the Journal for ImmunoTherapy of Cancer. These preclinical data further expand upon previously reported data that IO112 treatment inhibits tumor growth through dynamic changes in the tumor microenvironment. The present study showed how Arg1-specific T cells expanded by the vaccine enhance anti-tumor immunity by reprogramming tumor-associated macrophages, TAMS, and promote a proinflammatory TME. Arg1 plays a central role in immune suppression, and its overexpression has been reported in several cancers.